New hope for recurrent brain cancer? drug combo trial launches
NCT ID NCT07297212
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests two drugs, pumitamig and bevacizumab, alone or together with temozolomide, in 75 adults whose glioblastoma has returned after standard treatment. The goal is to see if these combinations can shrink tumors and control the disease. Participants will receive intravenous infusions or oral medication, and doctors will monitor for side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pumitamig (also called PM8002, BNT327, BMS-986545) and bevacizumab, with temozolomide in one arm
What this could lead to
If successful, this could point toward a new treatment option for people with recurrent glioblastoma, potentially shrinking tumors or slowing disease progression.
What could go wrong
This is an early phase 2 trial with only 75 participants, so results may not apply to everyone. The drugs may cause side effects, and there is no guarantee they will work better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, 250117, China
-
Affiliated Tumor Hospital of Chongqing Medical University
RECRUITINGChongqing, 350209, China
-
Beijing Tiantan Hospital, Capital Medical University
RECRUITINGBeijing, 100070, China
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, 201107, China
-
Shenzhen Second People's Hospital
RECRUITINGShenzhen, 518000, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, 430030, China